Ontology highlight
ABSTRACT:
PROVIDER: PRJNA343765 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR4293433.fastq.gz | Fastqsanger.gz | |||
| SRR4293304.fastq.gz | Fastqsanger.gz | |||
| SRR4293305.fastq.gz | Fastqsanger.gz | |||
| SRR4293306.fastq.gz | Fastqsanger.gz | |||
| SRR8816317_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 10 |
Similar Datasets
Project description:The mechanism(s) for therapeutic resistance against c-Met/receptor tyrosine kinase (RTK) inhibitor(s) in renal cancer is totally unexplored. In renal cell carcinoma (RCC) cells, both AXL and c-Met are highly overexpressed and they form a complex. Interestingly, the prolonged treatment with c-Met/RTK inhibitor, Cabozantinib (Cabo), which is being used for the treatment of RCC patients, markedly increased the level of total c-Met and promoted renal cancer cell proliferation. This effect was confirmed not only in vitro but also in murine models and renal tumor tissues from Cabo-treated patients. Also, the lower concentrations of Cabo treatment could not inhibit HGF (c-Met ligand)-induced c-Met phosphorylation; rather they further increased the phosphorylation of the receptor and promoted downstream signaling events for tumor growth. In addition, our findings indicate that Cabo treatment induces AXL-c-Met association, and it interferes with the physiological degradation processes of c-Met within renal cancer cells. However, either the inhibition or the knockout of AXL could significantly overcome the therapeutic resistance against c-Met inhibitor(s); and it markedly induced apoptotic cell death through increased oxidative stress and inhibition of the transcription factor, Nrf2. We generated Cabo-resistant RCC cells, and we observed that the expression of both c-Met and AXL are markedly overexpressed in these cells; and the inhibition of AXL (through TP-0903) can resensitize the cancer cells to Cabo-mediated cell death. Moreover, we found significant differences in the epigenomic profile of the Cabo-resistant RCC cells compared with Cabo-sensitive cancer cells. Our in-depth studies suggest that AXL plays a major role in mediating therapeutic resistance against c-Met inhibitor(s). A combination therapy using c-Met inhibitor(s) in the presence of an AXL inhibitor can play a pivotal role to overcome acquired resistance against RTK inhibitors in renal cancer.
2025-09-10 | GSE296078 | GEO
Project description:Marine microbial community from Cabo Rojo, Puerto Rico - PR CR 10% Liquid 1 metagenome
| PRJNA336694 | ENA
Project description:Marine microbial community from Cabo Rojo, Puerto Rico - PR CR 10% Liquid 3 metagenome
| PRJNA337758 | ENA
Project description:Marine microbial community from Cabo Rojo, Puerto Rico -PR CR 10% Liquid 2 metagenome
| PRJNA337757 | ENA
Project description:Marine sediment microbial community from Cabo Rojo, Puerto Rico - PR CR 10% Liquid 1 metagenome
| PRJNA366555 | ENA